Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation (Q42200351)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2006

Language	Label	Description	Also known as
English	Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation	scientific article published on June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation (English)

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

refractory anemia

1 reference

based on heuristic

inferred from title

Refractory anemia with ring sideroblasts

1 reference

based on heuristic

inferred from title

author name string

Hadrian Szpurka

1

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Ramon Tiu

2

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Gurunathan Murugesan

3

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Samer Aboudola

4

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Eric D Hsi

5

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Karl S Theil

6

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Mikkael A Sekeres

7

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Jaroslaw P Maciejewski

8

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

language of work or name

0 references

publication date

1 June 2006

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

108

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

7

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

2173-2181

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Focus on myeloproliferative diseases and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Signaling through the JAK/STAT pathway, recent advances and future challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

The Jak-STAT pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Functional interactions between Stat5 and the glucocorticoid receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

26 October 2017

Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

29 May 2018

Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

29 May 2018

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

29 May 2018

The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

17 August 2018

JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

17 August 2018

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

17 August 2018

STAT3 is constitutively active in some patients with Polycythemia rubra vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895556

17 August 2018

Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16741247

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2006-02-005751

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42200351&oldid=1935756251"